US equity indexes closed lower on Friday as crude oil prices jumped amid escalating attacks by the U
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares of the Maker of Robotic Surgical Tools Led S&P 500 Decliners on Friday
Revenue rose 19% and procedures grew 16%, but held guidance
Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
Revenue rose 19% and procedures grew 16%, but held guidance
Intuitive Surgical Stock Drops as Tariff Warning Tempers Strong Q2 Results
All three major US stock indexes were down Friday, as chipmakers led the way down on the final tradi
Intuitive Surgical (ISRG) is heading into a period of intensifying competitive headwinds and long-te
Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second...
According to TheFly, Citi lowered its price target to $500 from $590 and keeps a ‘Buy’ rating.
Investing.com - U.S. stock index futures fell sharply on Friday, pointing to a second straight day of losses on Wall Street as investors continued to reassess lofty technology valuations following a string of disappointing corporate updates tied to artificial intelligence spending.
Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.
Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.
Ahead of the bell Wall Street looks set to be headed for the red with US stock futures falling on Friday, leaving the major indices on course for weekly losses as the semiconductor sell-off rolled on. Dow Jones futures slipped 0.6%, and S&P 500 contracts dropped around...
Intuitive Surgical (ISRG) shares fell early Friday as growth in the company's da Vinci robotic surge
FEATURE Tech was getting hit again on Friday as investors carried on selling chip makers and other artificial-intelligence stocks. Futures tracking the slumped 1.8%. The and were both also on track to open lower.
Intuitive Surgical Inc. (NASDAQ:ISRG) shares fell sharply after the medical technology company released second-quarter results that topped Wall Street forecasts but issued a full-year procedure growth outlook that failed to meet investor expectations.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Intuitive Surgical is a leader in surgical robotics, and the stock has a history of deep drawdowns.
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Moby summary of Intuitive Surgical, Inc.'s Q2 2026 earnings call
Intuitive Surgical (NASDAQ:ISRG) reported a solid second quarter of 2026, with management pointing to continued global adoption of its da Vinci, da Vinci SP and Ion platforms, even as U.S. procedure growth moderated and China remained challenging. Chief Executive Officer Dave Rosa said total proced
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical issued lackluster procedure guidance for the year on Thursday, leading the stock to take a dive.
Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 18.5% year on year to $2.89 billion. Its non-GAAP profit of $2.80 per share was 11.9% above analysts’ consensus estimates. Stock drop is primarily driven by recent declines in overall surgery volumes, which were reported by major healthcare providers, as well as a recent Class II recall of certain da Vinci surgical components.
Wall Street is betting big on Ambarella's Physical AI opportunity.